NewAmsterdam Pharma Files 8-K
Ticker: NAMSW · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1936258
Sentiment: neutral
Topics: filing, regulatory
Related Tickers: NAP
TL;DR
NAP filing 8-K, likely routine updates, check for details.
AI Summary
On January 10, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that NewAmsterdam Pharma is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate high risk.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- January 10, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is NewAmsterdam Pharma Company N.V.
In which jurisdiction is NewAmsterdam Pharma Company N.V. incorporated?
NewAmsterdam Pharma Company N.V. is incorporated in The Netherlands.
What is the principal executive office address of the registrant?
The principal executive office address is Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
What is the registrant's telephone number?
The registrant's telephone number is +31 (0) 35 206 2971.
Filing Stats: 637 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-10 08:27:00
Filing Documents
- d837783d8k.htm (8-K) — 30KB
- d837783dex991.htm (EX-99.1) — 27KB
- d837783dex992.htm (EX-99.2) — 45KB
- g837783ex99_2p10g1.jpg (GRAPHIC) — 247KB
- g837783ex99_2p11g1.jpg (GRAPHIC) — 321KB
- g837783ex99_2p12g1.jpg (GRAPHIC) — 233KB
- g837783ex99_2p13g1.jpg (GRAPHIC) — 205KB
- g837783ex99_2p14g1.jpg (GRAPHIC) — 213KB
- g837783ex99_2p15g1.jpg (GRAPHIC) — 229KB
- g837783ex99_2p16g1.jpg (GRAPHIC) — 196KB
- g837783ex99_2p17g1.jpg (GRAPHIC) — 189KB
- g837783ex99_2p18g1.jpg (GRAPHIC) — 304KB
- g837783ex99_2p19g1.jpg (GRAPHIC) — 163KB
- g837783ex99_2p1g1.jpg (GRAPHIC) — 452KB
- g837783ex99_2p20g1.jpg (GRAPHIC) — 280KB
- g837783ex99_2p21g1.jpg (GRAPHIC) — 198KB
- g837783ex99_2p22g1.jpg (GRAPHIC) — 347KB
- g837783ex99_2p23g1.jpg (GRAPHIC) — 290KB
- g837783ex99_2p24g1.jpg (GRAPHIC) — 356KB
- g837783ex99_2p25g1.jpg (GRAPHIC) — 297KB
- g837783ex99_2p26g1.jpg (GRAPHIC) — 186KB
- g837783ex99_2p27g1.jpg (GRAPHIC) — 304KB
- g837783ex99_2p28g1.jpg (GRAPHIC) — 355KB
- g837783ex99_2p29g1.jpg (GRAPHIC) — 234KB
- g837783ex99_2p2g1.jpg (GRAPHIC) — 731KB
- g837783ex99_2p30g1.jpg (GRAPHIC) — 210KB
- g837783ex99_2p31g1.jpg (GRAPHIC) — 476KB
- g837783ex99_2p32g1.jpg (GRAPHIC) — 247KB
- g837783ex99_2p33g1.jpg (GRAPHIC) — 326KB
- g837783ex99_2p34g1.jpg (GRAPHIC) — 356KB
- g837783ex99_2p3g1.jpg (GRAPHIC) — 420KB
- g837783ex99_2p4g1.jpg (GRAPHIC) — 253KB
- g837783ex99_2p5g1.jpg (GRAPHIC) — 293KB
- g837783ex99_2p6g1.jpg (GRAPHIC) — 339KB
- g837783ex99_2p7g1.jpg (GRAPHIC) — 226KB
- g837783ex99_2p8g1.jpg (GRAPHIC) — 269KB
- g837783ex99_2p9g1.jpg (GRAPHIC) — 286KB
- 0001193125-25-004142.txt ( ) — 14104KB
- nams-20250110.xsd (EX-101.SCH) — 3KB
- nams-20250110_def.xml (EX-101.DEF) — 13KB
- nams-20250110_lab.xml (EX-101.LAB) — 22KB
- nams-20250110_pre.xml (EX-101.PRE) — 14KB
- d837783d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated January 10, 2025 99.2 NewAmsterdam Pharma Company N.V. Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: January 10, 2025